Business Description
EQRx Inc
NAICS : 541715
SIC : 2834
50 Hampshire Street, Cambridge, MA, USA, 02139
Description
EQRx Inc is a biotechnology company. Its pipeline programs include two pre-registrational oncology assets that have shown assuring Phase 3 data (aumolertinib and sugemalimab), and multiple other clinical-stage programs.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 617.45 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 0 | |||||
Beneish M-Score | 0 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 77.43 | |||||
9-Day RSI | 68.02 | |||||
14-Day RSI | 62.86 | |||||
6-1 Month Momentum % | 33.97 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 29.23 | |||||
Quick Ratio | 29.23 | |||||
Cash Ratio | 28.66 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | 2.35 | |||||
ROA % | 1.69 | |||||
ROIC % | -699.17 | |||||
ROC (Joel Greenblatt) % | -3922.32 | |||||
ROCE % | -14.38 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 138.16 | |||||
PE Ratio without NRI | 138.16 | |||||
PB Ratio | 1.79 | |||||
Price-to-Tangible-Book | 1.81 | |||||
EV-to-EBIT | -7.06 | |||||
EV-to-Forward-EBIT | -2.86 | |||||
EV-to-EBITDA | -7.07 | |||||
EV-to-Forward-EBITDA | -2.86 | |||||
EV-to-FCF | -8.7 | |||||
Price-to-Graham-Number | 3.34 | |||||
Price-to-Net-Current-Asset-Value | 1.83 | |||||
Price-to-Net-Cash | 1.87 | |||||
Earnings Yield (Greenblatt) % | -14.21 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:EQRX
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0 | ||
EPS (TTM) ($) | 0.043 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 62.86 | ||
14-Day ATR ($) | 0.408044 | ||
20-Day SMA ($) | 5.111 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range ($) | 2.63 - 8.6999 | ||
Shares Outstanding (Mil) | 487.76 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
EQRx Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |